Crizanlizumab Brand Name– ADAKVEO
What is Crizanlizumab
Crizanlizumab is an intravenous selectin blocker approved to reduce the frequency of vasoocclusive crises (VOC) in patients with sickle cell disease.
Crizanlizumab is the first targeted therapy approved for sickle cell disease. Approval was based on results of the SUSTAIN trial (n = 198), in which the median annual VOC rate was 1.63 for those receiving crizanlizumab 5 mg/kg, compared to 2.98 in the placebo group (indicating a 45.3% lower rate in the crizanlizumab group, p = 0.01).
Additionally, 36% of crizanlizumab-treated patients did not experience VOC during the study and it delayed time to first experienced VOC after treatment initiation from 1.4 to 4.1 months.
Common adverse reactions include back pain, nausea, fever, and arthralgia. Monitor patients for infusion-related reactions.
Crizanlizumab may interfere with automated platelet counts (platelet clumping), which can lead to unevaluable or falsely decreased platelet counts; run tests promptly or use citrate tubes.
- sickle cell disease
For the treatment of sickle cell disease, to reduce the frequency of vasoocclusive crises
NOTE: Crizanlizumab may be given with or without hydroxyurea.
- abdominal pain
- antibody formation
- back pain
- chest pain (unspecified)
- infusion-related reactions
- laboratory monitoring not necessary
- laboratory test interference
There are no drug interactions associated with Crizanlizumab products.